The purpose of this project is to address current and future treatment options for the neurogenic vascular disorder migraine. The project describes the pathophysiology of migraine in order to summarize the potential of treatments. Treatment options are limited to the painkilling drug triptan, and the possibly preventive treatment CGRP-antagonist. In order to discuss the specific potentials of the two treatment methods, this project relates to already existing trials were the effect of triptans and CGRP antagonists have been experimentally investigated, respectively. The theory is used for a discussion of the benefits and disadvantages of the two different treatment methods. The project will discuss the potential of the preventive treatment as well as a comparison between triptans and CGRP-antagonists and what problems the treatment options may involve. The report is based on already existing literature on migraine and clinical trials of the two treatments.
The project concludes, that antibodies has a potential as CGRP-antagonists for the treatment of migraine, but can’t replace all the current treatment methods in the present.
|Educations||Basic - Bachelor Study Program in Natural Science, (Bachelor Programme) Bachelor|
|Publication date||26 May 2019|
|Number of pages||31|
|Supervisors||Nils Ole Dalby|